Ozempic vs Retatrutide: Eli Lilly claims 'more than double' the weight loss in latest trial — What's next?

Mint - Oct 29, 2026

Retatrutide is widely expected to fuel Lilly's next wave of growth following the success of its Zepbound and Mounjaro.

Read full article

More News

Kick Connect
About Us

Kick Connect publishes a comprehensive overview of the latest news and theories on science & technology. We also report accurate news with a unique perspective on the world around us.